New Mexico Educational Retirement Board lessened its stake in Eli Lilly And Co (NYSE:LLY) by 10.8% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 72,608 shares of the company’s stock after selling 8,786 shares during the quarter. New Mexico Educational Retirement Board’s holdings in Eli Lilly And Co were worth $9,422,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Athena Capital Advisors LLC purchased a new position in shares of Eli Lilly And Co in the 4th quarter valued at about $26,000. Wakefield Asset Management LLLP purchased a new stake in Eli Lilly And Co during the 4th quarter worth approximately $27,000. Larson Financial Group LLC purchased a new stake in Eli Lilly And Co during the 4th quarter worth approximately $29,000. Ironwood Financial llc purchased a new stake in Eli Lilly And Co during the 4th quarter worth approximately $30,000. Finally, Trust Department MB Financial Bank N A increased its stake in Eli Lilly And Co by 54.7% during the 1st quarter. Trust Department MB Financial Bank N A now owns 232 shares of the company’s stock worth $30,000 after buying an additional 82 shares in the last quarter. 79.58% of the stock is owned by institutional investors and hedge funds.

In other news, SVP Alfonso G. Zulueta sold 4,000 shares of the business’s stock in a transaction that occurred on Thursday, January 31st. The stock was sold at an average price of $120.00, for a total transaction of $480,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Donald A. Zakrowski sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $127.01, for a total value of $127,010.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 867,382 shares of company stock worth $109,265,182. Insiders own 0.11% of the company’s stock.

LLY has been the subject of several research reports. UBS Group cut their price objective on Eli Lilly And Co from $107.53 to $100.00 and set an “average” rating for the company in a research note on Friday, February 8th. Argus reiterated a “buy” rating on shares of Eli Lilly And Co in a research note on Thursday, December 27th. Cantor Fitzgerald reiterated a “buy” rating on shares of Eli Lilly And Co in a research note on Monday, February 4th. Barclays reiterated a “buy” rating and set a $130.00 price objective on shares of Eli Lilly And Co in a research note on Sunday, January 20th. Finally, Zacks Investment Research upgraded Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $142.00 price objective for the company in a research note on Wednesday, April 10th. Ten investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $118.02.

Shares of Eli Lilly And Co stock opened at $115.20 on Friday. The company has a market cap of $119.33 billion, a PE ratio of 20.76, a P/E/G ratio of 2.35 and a beta of 0.33. Eli Lilly And Co has a 1-year low of $77.09 and a 1-year high of $132.13. The company has a debt-to-equity ratio of 1.07, a quick ratio of 1.38 and a current ratio of 1.73.

Eli Lilly And Co (NYSE:LLY) last issued its earnings results on Wednesday, February 6th. The company reported $1.33 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.36 by ($0.03). The company had revenue of $6.44 billion for the quarter, compared to analyst estimates of $6.28 billion. Eli Lilly And Co had a return on equity of 44.66% and a net margin of 13.16%. The company’s revenue for the quarter was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.14 earnings per share. As a group, analysts expect that Eli Lilly And Co will post 5.66 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “New Mexico Educational Retirement Board Has $9.42 Million Stake in Eli Lilly And Co (LLY)” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/new-mexico-educational-retirement-board-has-9-42-million-stake-in-eli-lilly-and-co-lly/2977253.html.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

See Also: Short Selling Stocks and Day Traders

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.